Revision History

A randomized, double-blind trial published in the American Journal of Psychiatry on May 19, 2026, found that a single ketamine infusion followed by four weeks of low-dose buprenorphine reduced suicidal ideation by 76% in adults with major depression — nearly double the 43% reduction seen in the ketamine-plus-placebo group. The trial enrolled only 50 patients, excluded people with substance use disorders, and was led by a researcher with a documented history of financial conflicts of interest in psychiatric drug development, raising questions about how much weight to place on the findings before larger replication studies are completed.